Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Prednisolone Pivalate→

Prednisolone Pivalate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1107-99-9
Molecular formula
C26H36O6
Molecular weight
444.6 g/mol
Drug class
Topical glucocorticoid corticosteroidprednisolone ester
Mechanism of action
An ester form of prednisolone that activates intracellular glucocorticoid receptors, suppressing inflammatory mediator synthesis and local immune-cell activity in skin. The pivalate ester affects the formulation and local delivery profile.
Indications / reported uses
  • Topical treatment of corticosteroid-responsive inflammatory skin disorders, including eczema and dermatitis, with the specific authorised product formulation.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=prednisolone%20pivalate · https://www.ncbi.nlm.nih.gov/mesh/?term=prednisolone+pivalate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Prednisolone Pivalate Environmental Risk Assessment (ERA) (the Prednisolone Pivalate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.